Biomarkers of platinum resistance in serous ovarian cancer

Authors

  • A. Rybin Odessa National Medical University

DOI:

https://doi.org/10.12775/JEHS.2025.85.65774

Keywords

ovarian cancer, platinum resistance, biomarkers

Abstract

The study was aimed to determine the platinum-resistance biomarkers in patients with ovarian cancer. The expression of ABCA1 is higher in platinum-resistant cases of ovarian cancer. The most pronounced relationship exists between the values of survivin expression, local activity of nitric oxide, the expression of glutathione dependent enzymes, the content of catecholamines in erythrocytes, and the expression of ABCA1 transporter

References

1. Epidemiology Working Group Steering Committee, Ovarian Cancer Association Consortium Members of the EWG SC, in alphabetical order:, Doherty JA, Jensen A, Kelemen LE, Pearce CL, Poole E, Schildkraut JM, Terry KL, Tworoger SS, Webb PM, Wentzensen N. Current Gaps in Ovarian Cancer Epidemiology: The Need for New Population-Based Research. J Natl Cancer Inst. 2023 Oct 1; 109(10).

2. Doherty JA, Peres LC, Wang C, Way GP, Greene CS, Schildkraut JM. Challenges and Opportunities in Studying the Epidemiology of Ovarian Cancer Subtypes. Curr Epidemiol Rep. 2017 Sep;4(3):211-220

3. Rybin, A., A. Varabina, and M. Broshkov. ""Epidemiology and management of ovarian cancer based on the clinical experience of the southern region of Ukraine." Georgian Medical News 288 (2019): 32-36.

4. Rybin A, Dubinina V, Kuznetsova O. Personalized managing of the patients with serous ovarian cancer. InINTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER 2016 Sep 1 (Vol. 26, pp. 35-35). TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA: LIPPINCOTT WILLIAMS & WILKINS.

5. Kolesnik O.O., Rybin A.I. Predicting the effectiveness of treatment for ovarian cancer patients. Current issues in paediatrics, obstetrics and gynaecology. – 2017. – No. 2. – pp. 40–47. DOI 10.11603/24116-4944.2017.2.8043.

6. Kolesnik O.O., Rybin A.I. Personalised treatment of ovarian cancer patients. Hospital Surgery. Journal named after L. Ya. Kovalchuk. – 2017. - No. 2 (78). – Pp. 5-12. DOI 10.11603/2414-4533.2017.2.7951.

7. Tkachenko O.I., Rybin A.I. Kuznetsova O.V. Prospective study of clinical effectiveness of differentiated treatment of ovarian cancer. Odessa Medical Journal. – 2017. - № 6. – S. 45-51. (in Ukrainian)

8. Bondar, O. V., Rybin, A. I., Maximovskyi, V. E., Kuznetsova, O. V., & Alieva, S. O. (2023). Optimizimg of management of the ovarian cancer patients with peritoneal carcinomatosis. Oncology, 25(3), 222-228. DOI: https://doi.org/10.15407/oncology.2023.03.222.

9. Rybin A. I., O. V. Kuznetsova, and V. E. Maximovsky. "Modern strategies of surgical treatment of patients with pelvic canceromatosis caused by the ovarian cancer. Visnyk morsʹkoyi medytsyny 2020; 2 (87): 55–61. DOI http://dx.doi.org/10.5281/zenodo.3967728.

10. Rybin A. (2022). Results of personalised treatment of ovarian cancer in patients with peritoneal carcinomatosis // Reproductive Health of Women, (7), 35–40. https://doi.org/10.30841/2708-8731.7.2022.272470.

11. RYBIN, A., MAKSYMOVSKYI, V., KUZNETSOVA, O. and ZAMYSHLYAK, V. Personalised treatment of patients with advanced ovarian cancer: comparative analysis of surgical approaches. Journal of Education, Health and Sport. Online. 30 June 2025. Vol. 83, p. 64576. DOI 10.12775/JEHS.2025.83.64576.

12. MAKSYMOVSKYI, V., RYBIN, A. and ZAMYSHLYAK, V. Quality of life in patients with advanced ovarian cancer under personalised treatment: the impact of HIPEC. Journal of Education, Health and Sport. Online. 11 August 2025. Vol. 84, p. 64751. DOI 10.12775/JEHS.2025.84.64751.

13. Rybin AI, Maksymovskyj VY, Pyrogov VV, Demidchik RY, Varabina AO. Comparative study of quality of life, adverse effects after cytoreduction and HIPEC in stage IIIA-IIIC ovarian cancer. J Educ Health Sport [Internet]. 2018 Oct. 31 8(10):412-7. DOI http://dx.doi.org/10.5281/zenodo.2456541

14. Rybin A.I. The role of proteomic and genetic predictors of survival in ovarian cancer patients. Clinical Oncology, 2016, No. 3 (23), pp. 46-48.

15. Prevention of pathological changes in the mammary glands in patients after surgery for uterine fibroids / S.G. Bugaysov, A.I. Rybin, A.E. Suprun // Oncology. — 2007. — Vol. 9, No. 2. — Pp. 129–132. https://nasplib.isofts.kiev.ua/handle/123456789/20479.

16. Rybin A. I., Lysenko M. A., Rysina A. I. Features of the sanogenesis system in patients with ovarian cancer resistant to platinum-based chemotherapy. Collection of scientific works of the Association of Obstetricians and Gynaecologists of Ukraine. 2014. 1-2. 251-254.

Journal of Education, Health and Sport

Downloads

Published

2025-09-25

How to Cite

1.
RYBIN, A. Biomarkers of platinum resistance in serous ovarian cancer. Journal of Education, Health and Sport. Online. 25 September 2025. Vol. 85, p. 65774. [Accessed 15 November 2025]. DOI 10.12775/JEHS.2025.85.65774.

Issue

Vol. 85 (2025)

Section

Medical Sciences

License

Copyright (c) 2025 A. Rybin

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0

Stats

Number of views and downloads: 144
Number of citations: 0